

**Epidemiology of the metabolic syndrome
in Luxembourg**
findings from ORISCAV-LUX study


Ala'a Alkerwi, MD, PhD

Nicolas Sauvageot, Marie-Lise Lair, Anne-Françoise Donneau, Adelin Albert, Michèle Guillaume

- ① Scope of the problem
- ② Rationale/motivation
- ③ Research objectives
- ④ Research methods
- ⑤ Results
- ⑥ Conclusion
- ⑦ Publications

- 1 Scope of the problem
- 2 Rationale/motivation
- 3 Research objectives
- 4 Research methods
- 5 Results
- 6 Conclusion
- 7 Publications

Metabolic Syndrome (MS)




MS is a multiplex cardio-metabolic disorder which clusters together in the same individual more often than might be expected by chance

Evolution of the MS criteria

Insulin resistance-based definitions

Obesity-based definitions



JIS 2009

3 or more of the following 5 criteria

- 1) \uparrow TG \geq 150 mg/dl or treatment
- 2) \downarrow HDL-C $<$ 40 mg/dl $\text{\textcircled{M}}$
 $<$ 50 mg/dl $\text{\textcircled{F}}$ or treatment
- 3) \uparrow SBP \geq 130 mmHg
DBP \geq 85 mmHg or treatment
- 4) \uparrow FPG \geq 100 mg/dl or treatment
- 5) **Waist Circumference (WC, cm) :**
population-specific cut-off points

simpler and more operational

Cardiovascular disease (CVD) risk prediction

Traditional risk assessment tools

Framingham
PROCAM
SCORE
others

Age, gender, family history, smoking


BP

LDL-C, HDL-C

Diabetes


Cardiovascular disease (CVD) risk prediction

Traditional risk assessment tools



- Traditional tools do not capture additional risk (obesity)
- MS alone can not improve prediction of global CVD risk
- Neither MS nor risk tools can properly assess global CVD risk


Global Cardio-Metabolic Risk concept



The “building blocks” of global cardiometabolic risk, with adaptation from Desprès et al 2008

- ① Scope of the problem
- ② Rationale/motivation
- ③ Research objectives
- ④ Research methods
- ⑤ Results
- ⑥ Conclusion
- ⑦ Publications

Geographical context



**Grand-Duchy of
Luxembourg**

**3 geographical districts
2586 km²**




493,500 inhabitants

Luxembourgers 56.3%

Foreigners 43.7%

Causes of mortality in Luxembourg (2007)




Directorate-General of Health, Luxembourg, 2007

Cardiovascular mortality in Europe

20-69 years

Highest mortality among
the Western countries


Age-standardized death rate per 100 000



European detailed mortality database (DMDDB)
Copenhagen, WHO Regional Office for Europe, 2006


MS (ATPIII definition)

Worldwide public health challenge



MS (ATPIII definition)

Worldwide public health challenge



- 1 Scope of the problem
- 2 Rationale/motivation
- 3 Research objectives**
- 4 Research methods
- 5 Results
- 6 Conclusion
- 7 Publications

Inductive exploratory approach

- Investigate the epidemiological profile of MS in the general resident population of Luxembourg
- Identify the potential socio-economic and behavioral determinants of MS

“Group at risk”

« *Evidence-based interventions* »

- 1 Scope of the problem
- 2 Rationale/motivation
- 3 Research objectives
- 4 Research methods**
- 5 Results
- 5 Conclusion
- 7 Publications



ORISCAV-LUX survey

Observation of Cardiovascular Risk Factors in Luxembourg

- 1st nationwide cross-sectional survey (November 2007-January 2009)
- Population of residents (18-69 years) of Luxembourg
- Stratified random sample of 1432 participants

Method of data collection

Mailing
(invitation/information)
with coupon-answer



Phone contact



Appointement



Investigation centre



1st step

IPAQ
FFQ
AUDIT

questionnaire

1. ...	<input type="checkbox"/>
2. ...	<input checked="" type="checkbox"/>
3. ...	<input type="checkbox"/>
4. ...	<input checked="" type="checkbox"/>
5. ...	<input checked="" type="checkbox"/>

2nd step



Waist and hip circumferences



Weight



Height



Blood pressure

3rd step



Hair sample



Urine



Blood



Sampling procedure (1)



Stratified random sample

District

- Diekirch
- Grevenmacher
- Luxembourg

Gender



Age category

18-69 y


National
Health
Insurance
Registry

The distribution of selected subjects in each stratum is proportional to their distribution in the source population

- ① Scope of the problem
- ② Rationale/motivation
- ③ Research objectives
- ④ Research methods
- ⑤ Results
- ⑥ Conclusion
- ⑦ Publications


Sample representativeness (1)

Comparison of participants to source population according to gender




Sample representativeness (2)

Comparison of participants to source population according to district



Sample representativeness (3)

Comparison of participants to source population according to age groups



Sample representativeness (4)

To assess whether the health status affected the response rate



Comparison between **participants** and **non-participants**

- Demographic indicators (profession, nationality)
- Morbidity indicators (prescribed medications, hospital admission and medical measures)

National medical administrative
database

Sample representativeness (4)

Conclusion*

Investigated clinical profile (hospital admission and cardiovascular health-related medical measures) was **comparable** in both groups (participants vs non-participants)



Response rate does **not invalidate** the results



Allows **generalizing** the findings for the population





*Alkerwi et al. BMC Medical Research Methodology 2010, 10:80

Metabolic syndrome

R-ATP III definition


Epidemiological profile (1)

3 or more of the following criteria

↑ WC  ≥ 102 cm  ≥ 88 cm
↓ HDL-C  < 40 mg/dl  < 50 mg/dl or treatment
↑ TG ≥ 150 mg/dl or treatment
↑ SBP ≥ 130 mmHg or treatment ↑ DBP ≥ 85 mmHg
↑ FPG ≥ 100mg/dl or diagnosed diabetes


Epidemiological profile (2)

Prevalence of metabolic syndrome by gender




Epidemiological profile (3)

Prevalence of metabolic syndrome by gender and age




Epidemiological profile (4)

Prevalence of metabolic syndrome components



Epidemiological profile (5)


Metabolic syndrome – Logistic regression Socio-economic factors



Reference category: married, university level of education, employed, working women, easy subjective economical status, above risk of poverty threshold

Epidemiological profile (6)


Metabolic syndrome – Logistic regression Lifestyle factors



Reference category: non-smokers, less than 10 cigarettes/day, physically active

Epidemiological profile (7)


Metabolic syndrome – Logistic regression Family history



Reference category: no family history of (hypertension, diabetes, myocardial infarction, CVA)

Epidemiological profile (8)


Metabolic syndrome – Logistic regression Dietary factors



Reference categories are those who respect the WHO recommendations, 2003

Epidemiological profile (9)

Metabolic syndrome – Logistic regression Final multivariate model



Conclusion

- The MS is an important health problem in Luxembourg (24.7%)
- MS increases remarkably with age in both genders
- Significant gender-specific differences
- Low education level, physical inactivity, inadequate protein diet and family history of diabetes and hypertension were the most important determinants of the MS
- Lifestyle-oriented intervention might be the promising approach for the primary prevention of MS

Added-values of the study

- **First reliable source of information for Luxembourg**
- **Provides scientific evidence for public health decision-makers**
- **Increases Luxembourg visibility at international level**
- **Model to reproduce the study in the neighboring regions**
- **Reinforcement of international collaboration**
- **Generates new hypotheses for future research**

Peer-reviewed publications

- 1) **Alkerwi** et al., Alcohol consumption and the prevalence of metabolic syndrome: A meta-analysis of observational studies, *Atherosclerosis*, 2009 vol. 204, no2, pp. 624-635.
- 2) **Alkerwi** et al., *First nationwide survey on cardiovascular risk factors in Grand-Duchy of Luxembourg (ORISCAV-LUX)*, *BMC Public Health* 2010, 10:468.
- 3) **Alkerwi** et al., *Comparison of participants and non-participants to the ORISCAV-LUX population-based study on cardiovascular risk factors in Luxembourg*, *Medical Research Methodology* 2010, 10:80.
- 4) **Alkerwi** et al., *Nutrition, environment and cardiovascular health (NESCAV): protocol of an inter-regional cross-sectional study*, *BMC Public Health* 2010, 10:698.
- 5) **Alkerwi** et al., *Prevalence of the metabolic syndrome in Luxembourg according to the Joint Interim Statement definition estimated from the ORISCAV-LUX study*, *BMC Public Health* 2011, 11:4.
- 6) **Alkerwi** et al., *Dietary, behavioral and socio-economic determinants of the metabolic syndrome among adults in Luxembourg: finding from ORISCAV-LUX study*”, *Public Health Nutrition*, doi:10.1017/S1368980011002278
- 7) **Alkerwi** et al., *Population compliance to dietary recommendations and its related factors: findings from ORISCAV-LUX study*, *submitted to British Journal of Nutrition, in July 2011.*

Financial support



LE GOUVERNEMENT
DU GRAND-DUCHÉ DE LUXEMBOURG
Ministère de la Culture, de l'Enseignement
supérieur et de la Recherche



LE GOUVERNEMENT
DU GRAND-DUCHÉ DE LUXEMBOURG
Ministère de la Santé



Programme Core 2010



Acknowledgements

Ministry of Health, Directorate of Health, Luxembourg

Ministry of Research, Luxembourg

General Inspectorat of Social Security

National Fund of Research

Luxembourgish Association of Cardiology, Luxembourg

Laboratory of the CHL, Luxembourg

Centre Hospitalier Emile Mayresch

Hôpital Saint Louis d'Ettelbruck

Hôpital Saint Joseph de Wiltz

Ligue Luxembourgeoise de Prévention et d'Action Médico-Sociale

Hellef Doheem, Luxembourg

School of Public Health, University of Liège, Belgium

CRP-Santé, Luxembourg

Thanks for your attention

